Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM-HF: Torsemide vs Furosemide in Heart Failure
NCT03296813Phase 3Completed
- Sponsor
- Duke University
- Start
- Jul 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of torasemide in heart failure (HF) (2 arms), sponsored by Duke University. Primary endpoint: All-cause Mortality at 30 months. Started Jul 2018; status: completed.
02
Drugs
torasemide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03296813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03296813.